-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
Colesevelam is a bile-sequestering agent approved in 2000 for the treatment of hypercholesterolemia. It has recently been shown to be effective as add-on therapy for Type 2 diabetics.
-
The available results from three ezetimibe/simvastatin trials did not provide credible evidence of any adverse effects of ezetimibe on the rate of cancer association with ezetimibe administration at the present time.
-
Leaders of the American Diabetes Association (ADA) joined with leaders of the European Association for the Study of Diabetes to reconsider the treatment strategy for patients with Type 2 diabetes.
-
-
Concussions, also known as mild traumatic brain injuries (mTBI), create challenges for the emergency care provider.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
Optimizing medical and lifestyle change therapy rather than performing PCI is appropriate as the initial management strategy for most patients with known CAD who do not have unstable or disabling symptoms.
-
Lifestyle changes plus red yeast rice and fish oil resulted in similar beneficial effects on LDL cholesterol as moderate-dose statin therapy in patients meeting criteria for drug therapy for high LDL cholesterol.
-